SpyGlass Pharma Inc.
SGP evidence brief
What we can confirm
- BioSniper Score:
- 7.7 / 10
- Market Cap:
- $956.6M
- Lead Asset:
- bim-drs (Phase 3)
What it means
What to watch
Prepared research question
What matters most for SGP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SGP
SpyGlass Pharma Inc. (SGP) is a biopharmaceutical company developing a bimatoprost drug-pad IOL system for cataract and glaucoma, with Phase 3 trials underway and $223.1M cash as of 2026-06-30.
Key risk: No approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$956.6M
Cash Runway
—
Lead Asset
bim-drs (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 6 clinical trials for SpyGlass Pharma Inc..
Similar companies
SpyGlass Pharma Inc. (SGP) is a biopharmaceutical company developing a bimatoprost drug-pad IOL system for cataract and glaucoma, with Phase 3 trials underway and $223.1M cash as of 2026-06-30.
- Cash & equivalents of $223.1M as of 2026-06-30 [sec].
- Net income of -$19.9M as of 2026-06-30 [sec].
- Shareholders' equity of $232.4M as of 2026-06-30 [sec].
- Phase 3 trials for bimatoprost drug pad-iol system (cataract) and bim-drs (glaucoma) started in October 2025 [catalyst].
- Positive top-line 12-month clinical updates on Bimatoprost Drug Pad-IOL System Phase 1/2 trial reported March 9, 2026 [news].
What works
- Cash position of $223.1M provides substantial runway for ongoing Phase 3 trials [sec].
- Positive 12-month clinical updates from Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System suggest promising efficacy and safety [news].
- Two Phase 3 programs (cataract and glaucoma) are underway, targeting large ophthalmic markets [catalyst].
What to weigh
- Net loss of $19.9M in the latest reported period indicates ongoing operational expenses without product revenue [sec].
- Glaucoma market is highly competitive with at least 184 competitors including Santen, PolyActiva, and Allergan [pipeline].
- The company has not yet reported any approved products or revenue from sales [sec].
From the filings
Quoted directly from source documents.
Phase 3 start for bimatoprost drug pad-iol system
“Phase3_Start: Phase3_Start: A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of the Bimatoprost Implant System (78 mcg) Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%”
Catalysts · October 28, 2025
Positive 12-month clinical updates
“positive top-line 12-month clinical updates on its innovative Bimatoprost Drug Pad-IOL System Phase 1/2 trial”
News · March 9, 2026
Catalyst timeline
- 2023-10-13 · Phase 2 start for bimatoprost implant system + SpyGlass IOL — A masked, controlled study evaluating safety, efficacy, and dose-response of the bimatoprost implant system combined with SpyGlass IOL.
- 2025-10-15 · Phase 3 start for bimatoprost implant system (78 mcg) + SpyGlass IOL — First Phase 3 trial start for the bimatoprost implant system (78 mcg) combined with SpyGlass IOL.
- 2025-10-28 · Phase 3 start for bimatoprost implant system (78 mcg) + SpyGlass IOL (second trial) — Second Phase 3 trial start for the same combination, indicating a parallel registration strategy.
Risks & what to watch (3)›
Key risks
- No approved products — Company has no marketed products and relies on cash reserves; net loss of $19.9M as of 2026-06-30 [sec].
- Intense glaucoma competition — At least 184 competitors in glaucoma, including Santen, PolyActiva, and Allergan [pipeline].
- Clinical trial execution risk — Phase 3 trials started in Oct 2025; outcomes and timelines are uncertain [catalyst].
What to watch
- Phase 3 data readouts for bimatoprost drug pad-iol system (cataract) and bim-drs (glaucoma) [catalyst].
- Cash runway and burn rate given net loss of $19.9M as of 2026-06-30 [sec].
- Regulatory interactions and potential FDA milestones [news].
- Competitor trial results, especially from Allergan's bimatoprost DDS and Santen's STN1012600 [competitor_trial].
Sources: Catalysts · Competitor trials · News · Pipeline · Generated October 12, 2026 · How we verify sources →
Run SpyGlass Pharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SpyGlass Pharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.05 · 0% dilution
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 8.0%
- Days to cover
- 11.8
- Shares short
- 884,597
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SGP short interestFrequently asked questions
What is the AI investment thesis for SpyGlass Pharma Inc.?
SpyGlass Pharma Inc. (SGP) is a biopharmaceutical company developing a bimatoprost drug-pad IOL system for cataract and glaucoma, with Phase 3 trials underway and $223.1M cash as of 2026-06-30.
What is SpyGlass Pharma Inc.'s lead drug candidate?
SpyGlass Pharma Inc.'s most advanced tracked candidate is bim-drs (Phase 3) for Glaucoma.
Who is the CEO of SpyGlass Pharma Inc.?
Mr. Patrick H. Mooney is the chief executive officer of SpyGlass Pharma Inc. (SGP).
Where is SpyGlass Pharma Inc. headquartered?
SpyGlass Pharma Inc. (SGP) is headquartered in Irvine, CA, United States.
What therapeutic areas does SpyGlass Pharma Inc. focus on?
SpyGlass Pharma Inc. develops therapies across Ophthalmology, Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.